Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent

Cytokine and Growth Factor Reviews

Volumn 38, Issue , 2017, Pages 10-21

  Guo, Yin ^a,b   Luan, Liming ^b   Patil, Naeem K ^b   Sherwood, Edward R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti viral immunotherapy; Cancer immunotherapy; IL 15 superagonist; IL 15 trans presentation; Memory CD8 T lymphocytes; Natural killer cells

Indexed keywords

ALT 803; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; COMPLEX FORMATION; CROSS REACTION; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; HUMAN; IMMUNOBIOLOGY; IMMUNOSTIMULATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; REVIEW; T LYMPHOCYTE ACTIVATION; AGONISTS; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASM; VIRUS INFECTION;

ANIMALS; GENETIC THERAPY; HUMANS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; NEOPLASMS; VIRUS DISEASES;

EID: 85028769651     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.08.002     Document Type: Review

References (95)

1. Grabstein, K.H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:5161 (1994), 965–968.
2. Castillo, E.F., Schluns, K.S., Regulating the immune system via IL-15 transpresentation. Cytokine 59:3 (2012), 479–490.
3. Dubois, S., Mariner, J., Waldmann, T.A., Tagaya, Y., IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17:5 (2002), 537–547.
4. Hutchins, N.A., Unsinger, J., Hotchkiss, R.S., Ayala, A., The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol. Med. 20:4 (2014), 224–233.
5. Carson, W.E., Giri, J.G., Lindemann, M.J., Linett, M.L., Ahdieh, M., Paxton, R., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:4 (1994), 1395–1403.
6. Jakobisiak, M., Golab, J., Lasek W: Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22:2 (2011), 99–108.
7. Neely, G.G., Epelman, S., Ma, L.L., Colarusso, P., Howlett, C.J., Amankwah, E.K., et al. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J. Immunol. 172:7 (2004), 4225–4234.
8. Fehniger, T.A., Caligiuri MA: Interleukin 15: biology and relevance to human disease. Blood 97:1 (2001), 14–32.
9. Ma, A., Koka, R., Burkett, P., Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24 (2006), 657–679.
10. Mattei, F., Schiavoni, G., Belardelli, F., Tough, D.F., IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167:3 (2001), 1179–1187.
11. Ahmad, R., Ennaciri, J., Cordeiro, P., El Bassam, S., Menezes, J., Herpes simplex virus-1 up-regulates IL-15 gene expression in monocytic cells through the activation of protein tyrosine kinase and PKC zeta/lambda signaling pathways. J. Mol. Biol. 367:1 (2007), 25–35.
12. Lucas, M., Schachterle, W., Oberle, K., Aichele, P., Diefenbach, A., Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26:4 (2007), 503–517.
13. Lodolce, J.P., Burkett, P.R., Koka, R.M., Boone, D.L., Ma, A., Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 13:6 (2002), 429–439.
14. Marcais, A., Cherfils-Vicini, J., Viant, C., Degouve, S., Viel, S., Fenis, A., et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15:8 (2014), 749–757.
15. Mao, Y., van Hoef, V., Zhang, X., Wennerberg, E., Lorent, J., Witt, K., et al. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood 128:11 (2016), 1475–1489.
16. Ali, A.K., Nandagopal, N., Lee, S.H., IL-15-PI3K-AKT-mTOR. a critical pathway in the life journey of natural killer cells. Front. Immunol., 6, 2015, 355.
17. Mortier, E., Quemener, A., Vusio, P., Lorenzen, I., Boublik, Y., Grotzinger, J., et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281:3 (2006), 1612–1619.
18. Norman, D.G., Barlow, P.N., Baron, M., Day, A.J., Sim, R.B., Campbell, I.D., Three-dimensional structure of a complement control protein module in solution. J. Mol. Biol. 219:4 (1991), 717–725.
19. Anderson, D.M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, A., et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J. Biol. Chem. 270:50 (1995), 29862–29869.
20. Dubois, S., Magrangeas, F., Lehours, P., Raher, S., Bernard, J., Boisteau, O., et al. Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression. J. Biol. Chem. 274:38 (1999), 26978–26984.
21. Wu, Z., Xue, H.H., Bernard, J., Zeng, R., Issakov, D., Bollenbacher-Reilley, J., et al. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation. Blood 112:12 (2008), 4411–4419.
22. Smith, X.G., Bolton, E.M., Ruchatz, H., Wei, X., Liew, F.Y., Bradley, J.A., Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival. J. Immunol. 165:6 (2000), 3444–3450.
23. Ruchatz, H., Leung, B.P., Wei, X.Q., McInnes, I.B., Liew, F.Y., Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160:11 (1998), 5654–5660.
24. Mortier, E., Bernard, J., Plet, A., Jacques, Y., Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J. Immunol. 173:3 (2004), 1681–1688.
25. Bouchaud, G., Garrigue-Antar, L., Sole, V., Quemener, A., Boublik, Y., Mortier, E., et al. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J. Mol. Biol. 382:1 (2008), 1–12.
26. Chertova, E., Bergamaschi, C., Chertov, O., Sowder, R., Bear, J., Roser, J.D., et al. Characterization and favorable in vivo properties of heterodimeric soluble IL-15: IL-15Ralpha cytokine compared to IL-15 monomer. J. Biol. Chem. 288:25 (2013), 18093–18103.
27. Thaysen-Andersen, M., Chertova, E., Bergamaschi, C., Moh, E.S., Chertov, O., Roser, J., et al. Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation. Glycoconj. J. 33:3 (2016), 417–433.
28. Cheng, L., Du, X., Wang, Z., Ju, J., Jia, M., Huang, Q., et al. Hyper-IL-15 suppresses metastatic and autochthonous liver cancers by promoting tumor-specific CD8 T cell responses. J. Hepatol., 2014.
29. Sun, H., Liu, D., IL-15/sIL-15Ralpha gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys. Cancer Gene Ther. 23:2–3 (2016), 54–60.
30. Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206:1 (2009), 25–34.
31. Bessard, A., Sole, V., Bouchaud, G., Quemener, A., Jacques, Y., High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol. Cancer Ther. 8:9 (2009), 2736–2745.
32. Vincent, M., Bessard, A., Cochonneau, D., Teppaz, G., Sole, V., Maillasson, M., et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int. J. Cancer 133:3 (2013), 757–765.
33. Ochoa, M.C., Fioravanti, J., Rodriguez, I., Hervas-Stubbs, S., Azpilikueta, A., Mazzolini, G., et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 73:1 (2013), 139–149.
34. Kermer, V., Baum, V., Hornig, N., Kontermann, R.E., Muller, D., An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol. Cancer Ther. 11:6 (2012), 1279–1288.
35. Rubinstein, M.P., Kovar, M., Purton, J.F., Cho, J.H., Boyman, O., Surh, C.D., et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. U. S. A. 103:24 (2006), 9166–9171.
36. Stoklasek, T.A., Schluns, K.S., Lefrancois, L., Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177:9 (2006), 6072–6080.
37. Guo, Y., Luan, L., Rabacal, W., Bohannon, J.K., Fensterheim, B.A., Hernandez, A., et al. IL-15 superagonist-Mediated immunotoxicity: role of NK cells and IFN-gamma. J. Immunol. 195:5 (2015), 2353–2364.
38. Wu, Z., Xu, Y., IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. J. Mol. Cell Biol. 2:4 (2010), 217–222.
39. Dubois, S., Patel, H.J., Zhang, M., Waldmann, T.A., Muller, J.R., Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J. Immunol. 180:4 (2008), 2099–2106.
40. Epardaud, M., Elpek, K.G., Rubinstein, M.P., Yonekura, A.R., Bellemare-Pelletier, A., Bronson, R., et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68:8 (2008), 2972–2983.
41. Xu, W., Jones, M., Liu, B., Zhu, X., Johnson, C.B., Edwards, A.C., et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73:10 (2013), 3075–3086.
42. Wong, H.C., Jeng, E.K., Rhode, P.R., The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity. Oncoimmunology, 2(11), 2013, e26442.
43. Mathios, D., Park, C.K., Marcus, W.D., Alter, S., Rhode, P.R., Jeng, E.K., et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int. J. Cancer 138:1 (2016), 187–194.
44. Rosario, M., Liu, B., Kong, L., Collins, L.I., Schneider, S.E., Chen, X., et al. The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin. Cancer Res. 22:3 (2016), 596–608.
45. Liu, B., Kong, L., Han, K., Hong, H., Marcus, W.D., Chen, X., et al. A novel fusion of ALT-803 (Interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses. J. Biol. Chem. 291:46 (2016), 23869–23881.
46. Felices, M., Chu, S., Kodal, B., Bendzick, L., Ryan, C., Lenvik, A.J., et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol. Oncol., 2017.
47. Kim, P.S., Kwilas, A.R., Xu, W., Alter, S., Jeng, E.K., Wong, H.C., et al. IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget 7:13 (2016), 16130–16145.
48. Gomes-Giacoia, E., Miyake, M., Goodison, S., Sriharan, A., Zhang, G., You, L., et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One, 9(6), 2014, e96705.
49. Eisenman, J., Ahdieh, M., Beers, C., Brasel, K., Kennedy, M.K., Le, T., et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20:3 (2002), 121–129.
50. Kobayashi, H., Dubois, S., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T.A., et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:2 (2005), 721–727.
51. Rowley, J., Monie, A., Hung, C.F., Wu, T.C., Inhibition of tumor growth by NK1. 1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. J. Immunol. 181:12 (2008), 8237–8247.
52. Morris, J.C., Ramlogan-Steel, C.A., Yu, P., Black, B.A., Mannan, P., Allison, J.P., et al. Vaccination with tumor cells expressing IL-15 and IL-15Ralpha inhibits murine breast and prostate cancer. Gene Ther. 21:4 (2014), 393–401.
53. Rowley, J., Monie, A., Hung, C.F., Wu, T.C., Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur. J. Immunol. 39:2 (2009), 491–506.
54. Hurton, L.V., Singh, H., Najjar, A.M., Switzer, K.C., Mi, T., Maiti, S., et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl. Acad. Sci. U. S. A. 113:48 (2016), E7788–E7797.
55. Mortier, E., Woo, T., Advincula, R., Gozalo, S., Ma, A., IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 205:5 (2008), 1213–1225.
56. Steel, J.C., Ramlogan, C.A., Yu, P., Sakai, Y., Forni, G., Waldmann, T.A., et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res. 70:3 (2010), 1072–1081.
57. Van den Bergh, J., Willemen, Y., Lion, E., Van Acker, H., De Reu, H., Anguille, S., et al. Transpresentation of interleukin-15 by IL-15/IL-15Ralpha mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget 6:42 (2015), 44123–44133.
58. Gaston, D.C., Odom, C.I., Li, L., Markert, J.M., Roth, J.C., Cassady, K.A., et al. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One, 8(11), 2013, e81768.
59. Tosic, V., Thomas, D.L., Kranz, D.M., Liu, J., McFadden, G., Shisler, J.L., et al. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PLoS One, 9(10), 2014, e109801.
60. Kokaji, A.I., Hockley, D.L., Kane, K.P., IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells. J. Immunol. 180:7 (2008), 4391–4401.
61. Waldmann, T.A., Tagaya, Y., The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17 (1999), 19–49.
62. McMichael, A.J., Environment, sustainability and health: the learning curve steepens. Med. J. Aust. 175:11–12 (2001), 569–570.
63. Mueller, Y.M., Bojczuk, P.M., Halstead, E.S., Kim, A.H., Witek, J., Altman, J.D., et al. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101:3 (2003), 1024–1029.
64. Kanai, T., Thomas, E.K., Yasutomi, Y., Letvin, N.L., IL-15 stimulates the expansion of AIDS virus-specific CTL. J. Immunol. 157:8 (1996), 3681–3687.
65. Fauci, A.S., Mavilio, D., Kottilil, S., NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5:11 (2005), 835–843.
66. Mavilio, D., Lombardo, G., Kinter, A., Fogli, M., La Sala, A., Ortolano, S., et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203:10 (2006), 2339–2350.
67. Chehimi, J., Marshall, J.D., Salvucci, O., Frank, I., Chehimi, S., Kawecki, S., et al. IL-15 enhances immune functions during HIV infection. J. Immunol. 158:12 (1997), 5978–5987.
68. Kottilil, S., Chun, T.W., Moir, S., Liu, S., McLaughlin, M., Hallahan, C.W., et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J. Infect. Dis. 187:7 (2003), 1038–1045.
69. Seay, K., Church, C., Zheng, J.H., Deneroff, K., Ochsenbauer, C., Kappes, J.C., et al. In vivo activation of human NK cells by treatment with an interleukin-15 superagonist potently inhibits acute In vivo HIV-1 infection in humanized mice. J. Virol. 89:12 (2015), 6264–6274.
70. Eberly, M.D., Kader, M., Hassan, W., Rogers, K.A., Zhou, J., Mueller, Y.M., et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J. Immunol. 182:3 (2009), 1439–1448.
71. Mueller, Y.M., Do, D.H., Altork, S.R., Artlett, C.M., Gracely, E.J., Katsetos, C.D., et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J. Immunol. 180:1 (2008), 350–360.
72. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:2 (2013), 134–144.
73. Di Giacomo, A.M., Danielli, R., Guidoboni, M., Calabro, L., Carlucci, D., Miracco, C., et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother.: CII 58:8 (2009), 1297–1306.
74. Conlon, K.C., Lugli, E., Welles, H.C., Rosenberg, S.A., Fojo, A.T., Morris, J.C., et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol., 2014.
75. Fehniger, T.A., Suzuki, K., Ponnappan, A., VanDeusen, J.B., Cooper, M.A., Florea, S.M., et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193:2 (2001), 219–231.
76. Mishra, A., Liu, S., Sams, G.H., Curphey, D.P., Santhanam, R., Rush, L.J., et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 22:5 (2012), 645–655.
77. Wege, A.K., Weber, F., Kroemer, A., Ortmann, O., Nimmerjahn, F., Brockhoff, G., IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget 8:2 (2017), 2731–2744.
78. Waldmann, T.A., Lugli, E., Roederer, M., Perera, L.P., Smedley, J.V., Macallister, R.P., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117:18 (2011), 4787–4795.
79. Chang, C.M., Lo, C.H., Shih, Y.M., Chen, Y., Wu, P.Y., Tsuneyama, K., et al. Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum. Gene Ther. 21:5 (2010), 611–621.
80. Pavlakis, M., Strehlau, J., Lipman, M., Shapiro, M., Maslinski, W., Strom, T.B., Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 62:4 (1996), 543–545.
81. Liu, Z., Geboes, K., Colpaert, S., D'Haens, G.R., Rutgeerts, P., Ceuppens, J.L., IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J. Immunol. 164:7 (2000), 3608–3615.
82. Rentzos, M., Cambouri, C., Rombos, A., Nikolaou, C., Anagnostouli, M., Tsoutsou, A., et al. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J. Neurol. Sci. 241:1–2 (2006), 25–29.
83. Guo, Y., Luan, L., Patil, N.K., Wang, J., Bohannon, J.K., Rabacal, W., et al. IL-15 enables septic shock by maintaining NK cell integrity and function. J. Immunol. 198:3 (2017), 1320–1333.
84. Herzig, D.S., Luan, L., Bohannon, J.K., Toliver-Kinsky, T.E., Guo, Y., Sherwood, E.R., The role of CXCL10 in the pathogenesis of experimental septic shock. Crit. Care, 18(3), 2014, R113.
85. Patil, N.K., Luan, L., Bohannon, J.K., Guo, Y., Hernandez, A., Fensterheim, B., et al. IL-15 superagonist expands mCD8+ T, NK and NKT cells after burn injury but fails to improve outcome during burn wound infection. PLoS One., 11(2), 2016, e0148452.
86. Herzig, D., Fang, G., Toliver-Kinsky, T.E., Guo, Y., Bohannon, J., Sherwood, E.R., STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock. Shock 38:4 (2012), 395–402.
87. Bohannon, J., Guo, Y., Sherwood, E.R., The role of natural killer cells in the pathogenesis of sepsis: the ongoing enigma. Crit. Care, 16(6), 2012, 185.
88. Herzig, D.S., Guo, Y., Fang, G., Toliver-Kinsky, T.E., Sherwood, E.R., Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis. Crit. Care, 16(5), 2012, R168.
89. Danai, P.A., Moss, M., Mannino, D.M., Martin, G.S., The epidemiology of sepsis in patients with malignancy. Chest 129:6 (2006), 1432–1440.
90. Williams, M.D., Braun, L.A., Cooper, L.M., Johnston, J., Weiss, R.V., Qualy, R.L., et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit. Care 8:5 (2004), R291–R298.
91. Elpek, K.G., Rubinstein, M.P., Bellemare-Pelletier, A., Goldrath, A.W., Turley, S.J., Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc. Natl. Acad. Sci. U. S. A. 107:50 (2010), 21647–21652.
92. Cheever, M.A., Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222 (2008), 357–368.
93. Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E., Walzer, T., Maturation of mouse NK cells is a 4-stage developmental program. Blood 113:22 (2009), 5488–5496.
94. Melero, I., Rouzaut, A., Motz, G.T., Coukos, G., T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 4:5 (2014), 522–526.
95. Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12:4 (2012), 237–251.